NASDAQ:APRE Aprea Therapeutics (APRE) Stock Price, News & Analysis $1.60 -0.15 (-8.57%) Closing price 05/21/2025 03:59 PM EasternExtended Trading$1.60 +0.00 (+0.31%) As of 05/21/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aprea Therapeutics Stock (NASDAQ:APRE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aprea Therapeutics alerts:Sign Up Key Stats Today's Range$1.60▼$1.7650-Day Range$1.47▼$2.4252-Week Range$1.41▼$5.30Volume16,521 shsAverage Volume22,165 shsMarket Capitalization$8.85 millionP/E RatioN/ADividend YieldN/APrice Target$15.50Consensus RatingBuy Company OverviewAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Read More… Aprea Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreAPRE MarketRank™: Aprea Therapeutics scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAprea Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAprea Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Aprea Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aprea Therapeutics are expected to grow in the coming year, from ($2.55) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aprea Therapeutics is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aprea Therapeutics is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAprea Therapeutics has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.24% of the float of Aprea Therapeutics has been sold short.Short Interest Ratio / Days to CoverAprea Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aprea Therapeutics has recently decreased by 0.66%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAprea Therapeutics does not currently pay a dividend.Dividend GrowthAprea Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.24% of the float of Aprea Therapeutics has been sold short.Short Interest Ratio / Days to CoverAprea Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aprea Therapeutics has recently decreased by 0.66%, indicating that investor sentiment is improving. News and Social Media1.6 / 5News Sentiment-0.16 News SentimentAprea Therapeutics has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Aprea Therapeutics this week, compared to 1 article on an average week.Search Interest1 people have searched for APRE on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Aprea Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Aprea Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,120.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.80% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.19% of the stock of Aprea Therapeutics is held by institutions.Read more about Aprea Therapeutics' insider trading history. Receive APRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address APRE Stock News HeadlinesQ2 Earnings Estimate for APRE Issued By WedbushMay 19 at 1:51 AM | americanbankingnews.comAprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical UpdateMay 14, 2025 | globenewswire.comHere’s your answerPorter Stansberry is stepping into the spotlight — and putting real skin in the game. For the first time ever, he’s opening the doors to a live, real-money trading account, managed transparently with the same strategies he’s used to build long-term wealth. Every 90 days, he and his lead analyst release a new tranche of trades designed for serious investors who don’t want to babysit the market. The goal: income, downside protection, and asymmetric upside.May 22, 2025 | Porter & Company (Ad)Halda Therapeutics Announces Appointment of Eyal Attar, MD, as Chief Medical OfficerApril 23, 2025 | finance.yahoo.comAprea Therapeutics Doses First Patient With HPV+ HNSCC In ACESOT-1051 TrialApril 2, 2025 | nasdaq.comAprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient DosingApril 2, 2025 | msn.comAprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trialApril 1, 2025 | finance.yahoo.comAprea Therapeutics announces dosing of patient with HPV+ HNSCC in trialApril 1, 2025 | markets.businessinsider.comSee More Headlines APRE Stock Analysis - Frequently Asked Questions How have APRE shares performed this year? Aprea Therapeutics' stock was trading at $3.29 on January 1st, 2025. Since then, APRE shares have decreased by 51.4% and is now trading at $1.60. View the best growth stocks for 2025 here. How were Aprea Therapeutics' earnings last quarter? Aprea Therapeutics, Inc. (NASDAQ:APRE) released its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.65) by $0.01. The company had revenue of $0.16 million for the quarter. Aprea Therapeutics had a negative trailing twelve-month return on equity of 57.86% and a negative net margin of 1,029.50%. When did Aprea Therapeutics' stock split? Aprea Therapeutics shares reverse split on the morning of Monday, February 13th 2023. The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Aprea Therapeutics IPO? Aprea Therapeutics (APRE) raised $52 million in an IPO on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO. Who are Aprea Therapeutics' major shareholders? Top institutional shareholders of Aprea Therapeutics include Stonepine Capital Management LLC (1.85%) and Exome Asset Management LLC (0.52%). Insiders that own company stock include Oren Gilad, Marc Duey, Bernd R Seizinger and John P Hamill. View institutional ownership trends. How do I buy shares of Aprea Therapeutics? Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aprea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aprea Therapeutics investors own include Tesla (TSLA), HubSpot (HUBS), Netflix (NFLX), Adverum Biotechnologies (ADVM), Biogen (BIIB), Sarepta Therapeutics (SRPT) and Corbus Pharmaceuticals (CRBP). Company Calendar Last Earnings5/14/2025Today5/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APRE CIK1781983 Webwww.aprea.com Phone617-463-9385FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$15.50 High Stock Price Target$20.00 Low Stock Price Target$11.00 Potential Upside/Downside+868.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,290,000.00 Net Margins-1,029.50% Pretax Margin-1,029.50% Return on Equity-57.86% Return on Assets-47.94% Debt Debt-to-Equity RatioN/A Current Ratio7.28 Quick Ratio7.28 Sales & Book Value Annual Sales$580,000.00 Price / Sales15.26 Cash FlowN/A Price / Cash FlowN/A Book Value$4.54 per share Price / Book0.35Miscellaneous Outstanding Shares5,531,000Free Float4,739,000Market Cap$8.85 million OptionableNo Data Beta1.18 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:APRE) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.